Search research articles
Contact Us
Filters
Showing results (151-160 of 195) with videos related to
Page
of 20
Sort By:
Biorxiv : the Preprint Server for Biology
|
March 17, 2025
RHOA Loss of Function Impairs the IFNγ Response and Promotes CD19 Antigen Escape to Drive CAR-T Resistance in Diffuse Large B-cell Lymphoma
Austin D Newsam, Bachisio Ziccheddu, Venu Venkatarame Gowda Saralamma, et al.
Blood
|
July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma
Hitomi Hosoya, Arash Velayati, Danai Dima, et al.
Blood Advances
|
June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Blood Advances
|
April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Satabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Blood Advances
|
July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Nausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Yucai Wang, Preetesh Jain, Frederick L Locke, et al.
Transplantation and Cellular Therapy
|
June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience
Jack Khouri, Danai Dima, Hong Li, et al.
The New England Journal of Medicine
|
June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Cancer Journal
|
August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 195) with videos related to
Sort By:
Page
of 20
Biorxiv : the Preprint Server for Biology
|
March 17, 2025
RHOA Loss of Function Impairs the IFNγ Response and Promotes CD19 Antigen Escape to Drive CAR-T Resistance in Diffuse Large B-cell Lymphoma
Austin D Newsam, Bachisio Ziccheddu, Venu Venkatarame Gowda Saralamma, et al.
Blood
|
July 8, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma
Hitomi Hosoya, Arash Velayati, Danai Dima, et al.
Blood Advances
|
June 12, 2023
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, et al.
Blood Advances
|
April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel
Satabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Blood Advances
|
July 24, 2025
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Nausheen Ahmed, Swetha Thiruvengadam, Mehdi Hamadani, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V Maus, Sara Alexander, Michael R Bishop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Yucai Wang, Preetesh Jain, Frederick L Locke, et al.
Transplantation and Cellular Therapy
|
June 4, 2024
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience
Jack Khouri, Danai Dima, Hong Li, et al.
The New England Journal of Medicine
|
June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Cancer Journal
|
August 9, 2023
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Christopher J Ferreri, Michelle A T Hildebrandt, Hamza Hashmi, et al.
Page
of 20